<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05078775</url>
  </required_header>
  <id_info>
    <org_study_id>NEAAR-001</org_study_id>
    <nct_id>NCT05078775</nct_id>
  </id_info>
  <brief_title>Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer</brief_title>
  <official_title>Prospective, Single Arm Medical Food Study to Evaluate a Standardized Nonessential Amino Acid Restriction (NEAAR) Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faeth Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faeth Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm study evaluating the tolerability and markers of pancreatic cancer with&#xD;
      a specially designed medical food restricted in specific amino acids for the dietary&#xD;
      management of subjects with locally advanced and unresectable or metastatic pancreatic&#xD;
      adenocarcinoma. Subjects who are eligible to receive two FDA approved first line drug&#xD;
      therapies, gemcitabine and nab-paclitaxel (gem+nabP), routinely prescribed in combination for&#xD;
      pancreatic cancer may be included in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate tolerability of the NEAAR medical food.</measure>
    <time_frame>Through study completion (average of 6 months)</time_frame>
    <description>The primary endpoint is the rate of the most common Grade 3 and 4 adverse event (AE) related to the NEAAR medical food.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rates</measure>
    <time_frame>Through study completion (average of 6 months)</time_frame>
    <description>Complete response and partial response using RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of best response</measure>
    <time_frame>Through study completion (average of 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biomarkers</measure>
    <time_frame>Through study completion (average of 6 months)</time_frame>
    <description>Absolute and relative change from baseline of disease biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Through study completion (average of 6 months)</time_frame>
    <description>Duration from radiographic documentation of disease to radiographic documentation of progression or death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <condition>Locally Advanced Unresectable Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Nonessential Amino Acid Restriction (NEAAR) Medical Food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single arm study in which all subjects will receive NEAAR medical food.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NEAAR Medical Food</intervention_name>
    <description>Standardized non-essential amino acid restricted medical food.</description>
    <arm_group_label>Nonessential Amino Acid Restriction (NEAAR) Medical Food</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form (ICF) by subject.&#xD;
&#xD;
          2. Histologically or cytologically confirmed pancreatic adenocarcinoma.&#xD;
&#xD;
          3. Locally advanced and unresectable or metastatic pancreatic adenocarcinoma.&#xD;
&#xD;
          4. Eligible for standard of care treatment with the gem+nabP regimen.&#xD;
&#xD;
          5. 18 years of age or older.&#xD;
&#xD;
          6. Measurable disease as determined by RECIST 1.1 (at least one measurable lesion must&#xD;
             not have been irradiated in the past).&#xD;
&#xD;
          7. ECOG Performance Status of ≤ 1.&#xD;
&#xD;
          8. Adequate organ function during screening evaluation&#xD;
&#xD;
          9. Available pancreatic adenocarcinoma tissue samples from a primary or metastatic site&#xD;
             that has been biopsied within the last 12 months and provide consent for them to be&#xD;
             obtained and analyzed by the study sponsor to assist in determining final eligibility.&#xD;
             A minimum of five (ten preferred) formalin fixed paraffin embedded (FFPE) archival or&#xD;
             fresh tumor tissue slides are required.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Any prior neoadjuvant or adjuvant therapy for pancreatic cancer within 6 months of&#xD;
             screening.&#xD;
&#xD;
          2. Any prior therapy for metastatic pancreatic cancer or locally advanced and&#xD;
             unresectable pancreatic cancer (except for neoadjuvant or adjuvant therapy as noted&#xD;
             above in exclusion criteria 1)&#xD;
&#xD;
          3. Known cerebral metastasis.&#xD;
&#xD;
          4. Diagnosis of another malignancy within the past 2 years (excluding a history of&#xD;
             carcinoma in situ of the cervix, superficial non-melanoma skin cancer, or superficial&#xD;
             bladder cancer that has been adequately treated, or stage 1 prostate cancer that does&#xD;
             not require treatment or requires only treatment with luteinizing hormone-releasing&#xD;
             hormone agonists or antagonists if initiated at least 30 days prior to beginning the&#xD;
             NEAAR medical food).&#xD;
&#xD;
          5. Body mass index (BMI) &lt;18.5 kg/m2 or &gt;40 kg/m2 or serious or refractive cachexia or&#xD;
             anorexia that, in the investigator's judgment, prohibits subjects from having energy&#xD;
             or appetite sufficient to reliably engage in a strict medical food regimen for an&#xD;
             extended time.&#xD;
&#xD;
          6. Presence of any significant comorbidity including clinically significant cardiac&#xD;
             disease (e.g., congestive heart failure, symptomatic coronary artery disease and&#xD;
             cardiac arrhythmias not well controlled with medication), myocardial infarction or&#xD;
             unstable angina within the 12 months prior to screening, or any major organ failure.&#xD;
&#xD;
          7. Known hypersensitivity, allergy, or religious restrictions regarding pork or&#xD;
             pork-derived products; or known allergy to any of the major food allergens as defined&#xD;
             by U.S. law (milk, eggs, fish, Crustacean shellfish, tree nuts, peanuts, wheat,&#xD;
             soybeans and sesame); or known allergy or hypersensitivity to , gemcitabine or&#xD;
             nab-paclitaxel, PERT products (e.g., Pancreaze), or formulary excipients in these&#xD;
             products (refer to the FDA-approved package insert).&#xD;
&#xD;
          8. Major surgery or significant traumatic injury within 14 days of planned start of NEAAR&#xD;
             medical food or the anticipation of the need for a major surgical procedure during the&#xD;
             study.&#xD;
&#xD;
          9. Unwillingness to consume small quantities of meat products and byproducts (e.g., fish&#xD;
             sauce, bone marrow, chicken broth).&#xD;
&#xD;
         10. Diagnosed with an eating disorder, irritable bowel syndrome (IBS), Crohn's disease,&#xD;
             ulcerative colitis, or gluten-sensitive enteropathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Hendifar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faeth Therapeutics</last_name>
    <phone>(708) 406-9282‬</phone>
    <email>info@faeththerapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Loughran</last_name>
      <phone>520-694-9057</phone>
      <email>bloughran@arizona.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900481804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigative Site</last_name>
      <phone>310-423-3277</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hoag Clinical Research</last_name>
      <phone>949-557-0290</phone>
    </contact>
    <contact_backup>
      <last_name>Backup</last_name>
      <phone>(949) 764-4577</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigative Site</last_name>
      <phone>239-274-9930</phone>
      <email>ClinicalTrials@FLCancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Atlantic Health</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Ginder, RN, BSN</last_name>
      <phone>973-971-6608</phone>
      <email>Nancy.Ginder@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Angela Alistar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>xCures - Virtual Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Ginn</last_name>
      <phone>919-649-4756</phone>
      <email>sginn@xcures.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethan Trull</last_name>
      <phone>615-982-2139</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baptist Hospitals of Southeast Texas</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Telice Terro</last_name>
      <phone>409-212-5979</phone>
      <email>telice.terro@bhset.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Health</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Dion</last_name>
      <phone>414-805-4639</phone>
      <email>badion@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>March 30, 2023</last_update_submitted>
  <last_update_submitted_qc>March 30, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

